Artificial intelligence could help prevent transplant complications by personalizing drug dosing

NCT ID NCT07695571

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This study aims to develop an artificial intelligence tool that helps doctors choose the right dose of cyclosporine for patients who have received a bone marrow transplant. Cyclosporine is used to prevent graft-versus-host disease, a serious complication where donor cells attack the patient's body. The tool combines information about how the drug behaves in the body with machine learning and deep learning techniques to predict the best dose using minimal blood samples. The goal is to make dosing more personalized and practical for everyday clinical care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
cyclosporine
What this could lead to
If successful, this AI tool could help doctors personalize cyclosporine doses for each patient, potentially reducing the risk of graft-versus-host disease after bone marrow transplant.
What could go wrong
This is a modeling study, not a treatment trial. The tool's predictions may not improve real-world outcomes, and its accuracy depends on the quality of the data used.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AML are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.